[
  {
    "ts": null,
    "headline": "PGIM Jennison Blend Fund Q1 2025 Commentary",
    "summary": "The PGIM Jennison Blend Fund underperformed the -4.7% return of the Russell 3000 Index during the quarter.",
    "url": "https://finnhub.io/api/news?id=f4b5f0e6516949d2c6f094c1549d294374f3a2284bb92a0b96dbe1b00bbada6e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746790200,
      "headline": "PGIM Jennison Blend Fund Q1 2025 Commentary",
      "id": 134345523,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1169704211/image_1169704211.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The PGIM Jennison Blend Fund underperformed the -4.7% return of the Russell 3000 Index during the quarter.",
      "url": "https://finnhub.io/api/news?id=f4b5f0e6516949d2c6f094c1549d294374f3a2284bb92a0b96dbe1b00bbada6e"
    }
  },
  {
    "ts": null,
    "headline": "Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV",
    "summary": "NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=bc909873394e9bfbbd74a84e5143963e9d6fac6cc9783c7b9a12bc71948e8480",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746769576,
      "headline": "Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV",
      "id": 134334890,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=bc909873394e9bfbbd74a84e5143963e9d6fac6cc9783c7b9a12bc71948e8480"
    }
  },
  {
    "ts": null,
    "headline": "Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).",
    "url": "https://finnhub.io/api/news?id=c23a8c9a47043b7709c88b614cf6723f3c69605ae4e91d4ce75f86cad1b4c7ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746761460,
      "headline": "Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks",
      "id": 134362266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).",
      "url": "https://finnhub.io/api/news?id=c23a8c9a47043b7709c88b614cf6723f3c69605ae4e91d4ce75f86cad1b4c7ff"
    }
  }
]